Cognition Therapeutics Inc (CGTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $64.65M
Last updated: Nov 17, 2026 at 4:38 PM ET
Cognition Therapeutics Inc (CGTX) Statistics
Cognition Therapeutics (CGTX) has a market cap of $64.65M and an enterprise value of $33.89M. Its share count is up 21.99% from a year earlier. Revenue fell 100.00% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 47.58% below the market cap, as cash exceeds debt.
| Market Cap | $64.65M |
|---|---|
| Enterprise Value | $33.89M |
| Latest price (Nov 17, 2026) | $0.63 |
Key Dates
The next earnings report is expected on Mar 24, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 24, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 5, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is down 59.36% over 52 weeks and trades 24.10% below its 50-day average.
| Beta (1Y) | 2.51 |
|---|---|
| 52-Week Change | -59.36% |
| 1-Month Change | -13.40% |
| 3-Month Change | -35.65% |
| 6-Month Change | -43.25% |
| 5-Year Change | -94.22% |
| Total Return (1Y) | -59.36% |
| Total Return (3Y CAGR) | -15.12% |
| Total Return (5Y CAGR) | -43.28% |
| Max Drawdown (1Y) | -66.97% |
| Max Drawdown (3Y) | -90.88% |
| Sharpe Ratio (1Y) | -0.87 |
| Correlation with SPY (1Y) | 0.34 |
| 50-Day Average | $0.83 |
| 200-Day Average | $1.03 |
| 52-Week Range | $0.55 to $1.81 |
| RSI (14 Days) | 31.8 |
| Average Volume (20 Days) | 415.32K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 6.68x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 6.68x |
|---|---|
| Quick Ratio | 6.68x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -54.64% over the last 12 months, against a 5-year average of -86.22%.
| Return on Equity (ROE) | -54.64% |
|---|---|
| Return on Assets (ROA) | -45.97% |
| Return on Capital Employed (ROCE) | -53.88% |
| ROE (5Y Average) | -86.22% |
| ROA (5Y Average) | -59.30% |
| ROIC (5Y Average) | -54.14% |
Scores
CGTX has a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 2 of 9 |
|---|---|
| Piotroski Strength | Weak |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Revenue Growth (YoY) | -100.00% |
| Gross Profit | -$61.00K |
| Operating Income | -$37.60M |
| Pretax Income | -$16.00M |
| Net Income | -$16.00M |
| EBITDA | -$15.77M |
| EBIT | -$15.99M |
| Reported EPS (TTM) | -$0.15 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 84.14% of the $34.80M in total assets.
| Cash and Equivalents | $30.76M |
|---|---|
| Total Debt | $0 |
| Net Cash | $30.76M |
| Net Cash Per Share | $0.32 |
| Working Capital | $29.11M |
| Shareholder Equity | $29.28M |
| Book Value Per Share | $0.31 |
| Total Assets | $34.80M |
| Total Liabilities | $5.53M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$15.29M |
|---|---|
| FCF Per Share | -$0.16 |
| Depreciation and Amortization | $217.00K |
Trailing 12 months through Sep 30, 2026.
Growth
| Book Value Per Share Growth (2Y CAGR) | -30.38% |
|---|---|
| Tangible Book Per Share Growth (2Y CAGR) | -30.38% |
Dividends and Yields
CGTX does not pay a dividend.
| Buyback Yield | -12.58% |
|---|---|
| Shareholder Yield | -12.58% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About CGTX
What is CGTX's market cap?
Cognition Therapeutics has a market cap of $64.65M. Its enterprise value, which adds debt and subtracts cash, is $33.89M.
How many shares of CGTX are outstanding?
Cognition Therapeutics has 95.10M shares outstanding. The count is up 21.99% from a year earlier.
Does CGTX pay a dividend?
No. Cognition Therapeutics does not pay a dividend.
How much debt does CGTX have?
Cognition Therapeutics has $0 of total debt and $30.76M of cash and equivalents, a net cash position of $30.76M.
CGTX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors